Wealth Effects LLC Makes New $273,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

Wealth Effects LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 4,000 shares of the medical device company's stock, valued at approximately $273,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Private Trust Co. NA increased its stake in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the period. Golden State Wealth Management LLC increased its stake in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the period. Optiver Holding B.V. purchased a new stake in DexCom in the fourth quarter worth $33,000. TD Private Client Wealth LLC increased its stake in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the period. Finally, Larson Financial Group LLC increased its stake in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Up 1.5%

DXCM stock traded up $1.29 during trading on Friday, reaching $86.33. 4,632,374 shares of the company traded hands, compared to its average volume of 4,389,290. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.19. The business has a 50 day simple moving average of $81.70 and a 200 day simple moving average of $79.59. The company has a market capitalization of $33.85 billion, a price-to-earnings ratio of 64.43, a price-to-earnings-growth ratio of 1.84 and a beta of 1.46. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the business earned $0.32 EPS. DexCom's revenue for the quarter was up 12.5% compared to the same quarter last year. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on DXCM. Barclays increased their target price on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Robert W. Baird reduced their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Canaccord Genuity Group increased their target price on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Truist Financial initiated coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target on the stock. Finally, Wall Street Zen downgraded DexCom from a "buy" rating to a "hold" rating in a research report on Sunday. Five equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $98.50.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $41,400.00. Following the completion of the sale, the executive vice president now owns 95,102 shares of the company's stock, valued at approximately $7,874,445.60. This trade represents a 0.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,724 shares of company stock valued at $2,157,034 over the last quarter. 0.32% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.